866-997-4948(US-Canada Toll Free)

Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth

Published By :

GBI Research

Published Date : Sep 2014

Category :

Therapeutic Area

No. of Pages : N/A

GBI Research, a leading business intelligence provider, has released its latest research report “Melanoma Therapeutics Market to 2020 - Rising Prevalence and Evolving Treatment Algorithms to Drive Market Growth.”

Melanoma is a highly heterogeneous disease comprising Cutaneous Melanoma (CM), Ocular Melanoma (OM), Mucosal Melanoma (MM), melanoma of the internal organs, and, according to some classifications, melanoma of the soft parts (non-bony and non-cartilaginous tissues) of the body. CM is by far the most common form of melanoma, accounting for approximately 90–95% of all melanomas.

Historically, melanoma has been considered as a very challenging disease to treat with pharmacotherapy. However, in recent years, understanding of the pathophysiology and heterogeneity of melanoma, and particularly CM, has developed considerably. This has led to the approval of several new drug agents indicated for CM since 2011, namely Sylatron (peginterferon alfa-2b), Yervoy (ipilimumab), Opdivo, (nivolumab), Keytruda (pembrolizumab), Zelboraf (vemurafenib), Tafinlar (dabrafenib) and Mekinist (trametinib). These drugs have dramatically improved the treatment options for CM patients, leading to unprecedented market growth.

Rapid market growth is also anticipated over the forecast period due to the expanding melanoma treatment population and the continued uptake of recently approved drugs. The melanoma pipeline is currently strong, with several promising molecules in development including, Polynoma’s seviprotimut-L, Amgen’s talimogene laherparepvec (T-VEC) and Roche and Genentech’s cobimetinib in combination with Zelboraf, which are in development for CM, as well as AstraZeneca’s selumetinib which is in development for OM. Consequently, the melanoma therapeutics market is projected to grow from $1.3 billion in 2013 to $3.6 billion in 2020, at a CAGR of 15.4%.

Scope

The report analyzes treatment usage patterns, drug types available and pipeline and market forecasts across indications for melanoma.

The report covers and includes:

  • An introduction to the melanoma indication, including disease symptoms, epidemiology, etiology, pathophysiology, staging, diagnosis and treatment.
  • In-depth analysis of the current melanoma marketed products landscape including product profiles of the main drugs used in melanoma and heat maps that compare safety and efficacy parameters of the various drugs.
  • Comprehensive analysis of the melanoma pipeline by phase of development, molecule type, molecular target and novelty. A comparative analysis of late-stage pipeline drugs that are likely to enter the market in the forecast period is also provided alongside heat maps.
  • Additional in-depth analysis of melanoma clinical trials by size, duration, failure rates and primary and secondary endpoints.
  • Multi-scenario forecast data for the market to 2020, taking into account how it will be affected by the introduction of new drugs and changes in disease epidemiology across the key developed markets, the US, Canada, the UK, France, Germany, Italy, Spain and Japan.
  • Discussion of the licensing and co-development strategic consolidations landscape in melanoma, by Phase of development and molecule type, as well as an analysis of both licensing and co-development deals by year, and network maps of licensing and co-development deals.

Reasons To Buy

The report will assist business development and enable marketing executives to strategize their product launches, by allowing them to:

  • Gain a comprehensive understanding of the melanoma indication including segmentation of disease and treatment algorithms.
  • Understand the current melanoma marketed products landscape and recognize the dominant therapeutic agents and pharmaceutical players involved.
  • Identify trends and developments within the melanoma pipeline including which molecule types and molecular targets are prominent.
  • Consider market opportunities and potential risks by examining trends in melanoma clinical trial duration and size, as well as clinical trial failure rates, amongst clinical trial Phases and molecule types.
  • Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the melanoma therapeutics market.
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 Introduction
2.1 Disease Introduction
2.2 Types of Melanoma
2.3 Symptoms
2.3.1 Cutaneous Melanoma
2.3.2 Ocular Melanoma
2.3.3 Mucosal Melanomas
2.3.4 Melanomas of the Internal Organs and Soft Parts
2.3.5 Advanced Melanoma
2.4 Etiology and Risk Factors
2.4.1 Phenotypic Characteristics
2.4.2 Exposure to Ultraviolet Radiation
2.4.3 Personal or Family History of Melanoma
2.4.4 Xeroderma Pigmentosum
2.4.5 Parkinson’s Disease
2.5 Pathophysiology
2.5.1 Cutaneous Melanoma
2.5.2 Ocular Melanoma
2.5.3 Mucosal Melanoma
2.5.4 Underlying Molecular Pathways
2.6 Melanoma Staging
2.7 Diagnosis
2.7.1 Cutaneous Melanoma
2.7.2 Ocular Melanoma
2.7.3 Mucosal Melanoma
2.8 Epidemiology
2.8.1 Cutaneous Melanoma
2.8.2 Ocular Melanoma
2.8.3 Mucosal Melanoma
2.9 Treatment Options
2.9.1 Surgery
2.9.2 Radiation Therapy
2.9.3 Pharmacotherapy
2.10 Treatment Algorithms
2.10.1 Cutaneous Melanoma
2.10.2 Ocular Melanoma
2.10.3 Mucosal Melanoma
2.11 Treatment Segments
2.11.1 Adjuvant Therapy for CM (All Mutations)
2.11.2 Advanced Therapy for CM (All Mutations)
2.11.3 Advanced Therapy for CM (BRAF Mutated Patients Only)

3 Marketed Products
3.1 Overview
3.2 Adjuvant therapy
3.2.1 Immunotherapy
3.3 Therapy for Advanced (Unresectable or Metastatic) Melanoma
3.3.1 Chemotherapy
3.3.2 Immunotherapy
3.3.3 Targeted Therapies
3.4 Heat Maps for Marketed Products

4 Melanoma Pipeline
4.1 Overview
4.2 Pipeline Distribution by Phase of Development, Molecule Type, Route of Administration and Novelty
4.3 Pipeline Distribution by Molecular Target
4.4 Clinical Trial Landscape
4.4.1 Clinical Trial Failure Rates
4.4.2 Clinical Trial Duration
4.4.3 Clinical Trial Size
4.4.4 Primary and Secondary Endpoints
4.5 Promising Pipeline Molecules
4.5.1 Adjuvant Immunotherapy
4.5.2 Advanced Disease Immunotherapy
4.5.3 Advanced Disease Targeted Therapy
4.6 Heat Map and Competitor Matrix for Pipeline Products

5 Market Forecast to 2020
5.1 Geographical Markets
5.2 Global Market
5.3 North America
5.3.1 Treatment Usage Patterns
5.3.2 Annual Cost of Therapy
5.3.3 Market Size
5.4 Top Five EU Markets
5.4.1 Treatment Usage Patterns
5.4.2 Annual Cost of Therapy
5.4.3 Market Size
5.5 Japan
5.5.1 Treatment Usage Patterns
5.5.2 Annual Cost of Therapy
5.5.3 Market Size
5.6 Driver and Barriers for the Melanoma Therapeutics Market
5.6.1 Drivers
5.6.2 Barriers

6 Strategic Consolidations
6.1 Overview
6.2 Co-development Deals
6.2.1 GlaxoSmithKline Enters into Co-development Agreement with Synta Pharma for elesclomol (STA-4783) – Deal Now Terminated
6.2.2 Exelixis Enters into Co-development Agreement with Genentech for cobimetinib
6.2.3 Roche Enters into Co-development Agreement with Bristol-Myers Squibb for Zelboraf/Yervoy Combination Drug - No Longer Under Development for Melanoma
6.3 Licensing Deals
6.3.1 Chugai Pharma Enters into Licensing Agreement with Roche for Zelboraf
6.3.2 Colby Enters into Licensing Agreement with MannKind for Cancer Immunotherapy Products – No Longer Under Development for Melanoma
6.3.3 Molecular Insight Enters into Licensing Agreement with Bayer Schering Pharma for Solazed – No Longer Under Development for Melanoma - No Longer Under Development for Melanoma

7 Appendix
7.1 All Pipeline Drugs by Phase of Development
7.1.1 Discovery
7.1.2 Preclinical
7.1.3 IND/CTA-filed
7.1.4 Phase I
7.1.5 Phase II
7.1.6 Phase III
7.1.7 Pre-registration
7.2 Market Forecasts to 2020
7.2.1 Global
7.2.2 US
7.2.3 Canada
7.2.4 UK
7.2.5 France
7.2.6 2.2.6 Germany
7.2.7 Italy
7.2.8 Spain
7.2.9 Japan
7.3 References
7.3.1 References for Heat Maps
7.4 Abbreviations
7.5 Research Methodology
7.5.1 Secondary Research
7.5.2 Marketed Product Profiles
7.5.3 Late-Stage Pipeline Candidates
7.5.4 Comparative Efficacy and Safety Heat Map for Marketed and Pipeline Products
7.5.5 Product Competitiveness Framework
7.5.6 Pipeline Analysis
7.5.7 Forecasting Model
7.5.8 Deals Data Analysis
7.6 Contact Us
7.7 Disclaimer

List of Table

Table 1: Characteristics of Types of Melanoma
Table 2: Staging of Cutaneous Melanoma
Table 3: Melanoma Clinical Trial Endpoint Definitions
Table 4: Melanoma Therapeutics Market, Global, Pipeline, Groups of Molecular Targets, 2014
Table 5: Breakdown of ‘Other’ Molecular Targets
Table 6: Breakdown of Molecular Target Combinations
Table 7: Melanoma Therapeutics, Global, All Pipeline Products, Discovery Phase, 2014
Table 8: Melanoma Therapeutics, Global, All Pipeline Products, Preclinical Phase, 2014
Table 9: Melanoma Therapeutics, Global, All Pipeline Products, IND/CTA-filed Phase, 2014
Table 10: Melanoma Therapeutics, Global, All Pipeline Products, Phase I, 2014
Table 11: Melanoma Therapeutics, Global, All Pipeline Products, Phase II, 2014
Table 12: Melanoma Therapeutics, Global, All Pipeline Products, Phase III, 2014
Table 13: Melanoma Therapeutics, Global, All Pipeline Products, Pre-registration Phase, 2014
Table 14: Melanoma Therapeutics Market, Global, Market Forecast, 2013–2020
Table 15: Melanoma Therapeutics Market, US, Market Forecast, 2013–2020
Table 16: Melanoma Therapeutics Market, Canada, Market Forecast, 2013–2020
Table 17: Melanoma Therapeutics Market, UK, Market Forecast, 2013–2020
Table 18: Melanoma Therapeutics Market, France, Market Forecast, 2013–2020
Table 19: Melanoma Therapeutics Market, Germany, Market Forecast, 2013–2020
Table 20: Melanoma Therapeutics Market, Italy, Market Forecast, 2013–2020
Table 21: Melanoma Therapeutics Market, Spain, Market Forecast, 2013–2020
Table 22: Melanoma Therapeutics Market, Japan, Market Forecast, 2013–2020
Table 23: List of Abbreviations

List of Chart

Figure 1: Melanoma Therapeutics Market, Global, Heat Map for Adjuvant Marketed Products, 2014
Figure 2: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products, 2014
Figure 3: Melanoma Therapeutics Market, Global, Heat Map for Advanced Marketed Products, 2014 (continued)
Figure 4: Melanoma Therapeutics Market, Global, Pipeline, 2014
Figure 5: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Biologics and Gene/Cell Therapies, 2014
Figure 6: Melanoma Therapeutics Market, Global, Pipeline, Repositioned Molecules by Original Indication, 2014
Figure 7: Melanoma Therapeutics Market, Global, Pipeline by Molecular Target, 2014
Figure 8: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Protein Kinase Molecular Targets by Phase of Development, 2014
Figure 9: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Antigens/Antigen Ligands Molecular Targets by Phase of Development, 2014
Figure 10: Melanoma Therapeutics Market, Global, Pipeline, Breakdown of Cytokine/Cytokine Receptor Molecular Targets by Phase of Development, 2014
Figure 11: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates by Phase of Development and Overall Clinical Trial Attrition Rate, 2006–2013 (%)
Figure 12: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates (Phases I, II and III) and Clinical Trial Attrition Rate by Molecule Type (%), 2006–2013
Figure 13: Melanoma Therapeutics Market, Global, Clinical Trial Failure Rates (Phases I, II and III) and Clinical Trial Attrition Rate by Molecular Target (%), 2006–2013
Figure 14: Melanoma Therapeutics Market, Global, Pipeline, Clinical Trial Duration by Molecule Type (months), 2006–2013
Figure 15: Melanoma Therapeutics Market, Global, Clinical Trial Size by Molecule Type (participants), 2006–2013
Figure 16: Melanoma Therapeutics Market, Global, Failure Rate, Average Trial Duration and Average Trial Recruitment Size by Molecule Type, 2006–2013
Figure 17: Melanoma Therapeutics Market, Global, Pipeline, Primary Clinical Trial Endpoints by Phase of Development (%), 2006–2013
Figure 18: Melanoma Therapeutics Market, Global, Breakdown of Safety/drug Biochemistry and Efficacy Clinical Trial Primary Endpoints by Phase of Development, 2006–2013
Figure 19: Melanoma Therapeutics Market, Global, Secondary Clinical Trial Endpoints by Phase of Development (%), 2006–2013
Figure 20: Melanoma Therapeutics Market, Global, Breakdown of Safety/drug biochemistry, Efficacy and ‘Other’ Clinical Trial Secondary Endpoints by Phase of Development, 2006–2013
Figure 21: Melanoma Therapeutics Market, Global Sales Forecast for Seviprotimut-L ($m), 2017–2020
Figure 22: Melanoma Therapeutics Market, Global, Sales Forecast for Yervoy (Adjuvant Setting) ($m), 2016–2020
Figure 23: Melanoma Therapeutics Market, Global Sales Forecast for Talimogene Laherparepvec (T-Vec) ($m), 2015–2020
Figure 24: Melanoma Therapeutics Market, Global, Sales Forecast for Selumetinib ($m), 2016–2020
Figure 25: Melanoma Therapeutics Market, Global Sales Forecast for Binimetinib ($m), 2016–2020
Figure 26: Melanoma Therapeutics Market, Global, Sales Forecast for Cobimetinib ($m), 2015–2020
Figure 27: Melanoma Therapeutics Market, Global, Heat Map for Adjuvant Pipeline Products, 2014
Figure 28: Melanoma Therapeutics Market, Global, Heat Map for Advanced Pipeline Products, 2014
Figure 29: Melanoma Therapeutics Market, Global, Heat Map for Advanced Pipeline Products, 2014 (continued)
Figure 30: Melanoma Therapeutics Market, Global, Competitor Matrix for Advanced Products, 2014
Figure 31: Melanoma Therapeutics Market, Global, Treatment Patterns (‘000) and Market Size ($bn), 2013–2020
Figure 32: Melanoma Therapeutics Market, North America, Treatment Patterns, 2013–2020
Figure 33: Melanoma Therapeutics Market, North America, Annual Cost of Therapy ($), 2013–2020
Figure 34: Melanoma Therapeutics Market, North America, Market Size, 2013–2020
Figure 35: Melanoma Therapeutics Market, Five EU Countries, Treatment Patterns (‘000), 2013–2020
Figure 36: Melanoma Therapeutics Market, Top Five EU Countries, Annual Cost of Therapy ($), 2013–2020
Figure 37: Melanoma Therapeutics Market, Top Five EU Countries, Market Size ($m), 2013–2020
Figure 38: Melanoma Therapeutics Market, Japan, Treatment Usage Patterns (‘000), 2013–2020
Figure 39: Melanoma Therapeutics Market, Japan, Annual Cost of Therapy ($), 2013–2020
Figure 40: Melanoma Therapeutics Market, Japan, Market Size ($m), 2013–2020
Figure 41: Melanoma Therapeutics Market, Global, Co-development Deals by Region, 2006–2014
Figure 42: Melanoma Therapeutics Market, Global, Co-development Deals by Deal Value, 2006–2014
Figure 43: Melanoma Therapeutics Market, Global, Co-development Deals by Year, 2006–2014
Figure 44: Melanoma Therapeutics Market, Global, Co-development Deals by Phase of Development, Deal Value and Upfront Payment ($m), 2006–2014
Figure 45: Melanoma Therapeutics Market, Co-development Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006–2014
Figure 46: Melanoma Therapeutics Market, Global, Licensing Deals by Region, 2006–2014
Figure 47: Melanoma Therapeutics Market, Global, Licensing Deals by Deal Value, 2006–2014
Figure 48: Melanoma Therapeutics Market, Global, Licensing Deals by Year, 2006–2014
Figure 49: Melanoma Therapeutics Market, Global, Licensing Deals by Phase of Development, Deal Value and Upfront Payment ($m), 2006–2014
Figure 50: Melanoma Therapeutics Market, Licensing Deals by Phase of Development, Molecule Type and Aggregate Deal Value ($m), 2006–2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *